Unlock the full potential of Medical Affairs teams in the pharmaceutical industry to address complex challenges and lead strategic decision-making.
All articles:
PROs: Can patients ‘co-develop’ their treatment?
Discover the value of patient-reported outcomes (PROs) in clinical trials and how they can help address unmet needs in ovarian cancer.
Harnessing AI to revolutionise clinical trials
Discover how digital twins and synthetic control arms can revolutionise drug development. Learn about their impact on precision medicine and patient outcomes.
How to measure the value of Medical Affairs teams
Discover how to redefine qualitative and quantitative metrics in Medical Affairs to improve patient outcomes whilst demonstrating value to the organisation.
The future of biotechnology: redefining undruggable targets
Martin Guppy shares his views on what the future of drug discovery may look like
San Francisco seeking to be the world’s top biotech cluster
Cambridge in the greater Boston area calls itself the most innovative square mile on the planet but San Francisco’s Bay Area is snapping at it heels
Where is the most innovative square mile on the planet?
How did Kendall Square in Cambridge, Massachusetts become the centre of the world’s largest biotech hub?
Why US biotechs increasingly choose Switzerland for their European HQ
Why a combination of talent, tax, environment and infrastructure makes Switzerland a particularly attractive option for US biotechs.
When is a European Biotech going to match its US counterparts?
Despite the hurdles,there is optimism that a European biotech will emerge as a global marketing success
Understanding Generation Z
Generation Z (born between 1995-2010) is attracting much discussion about what its attitudes to social issues, gender politics and the workplace mean for corporations, brands and other institutions. In this article we explore how this generation’s experiences and expectations are likely to shape the future of healthcare.